Chardan Capital assumed coverage on shares of iBio (NYSE:IBIO – Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $5.00 price target on the stock. Separately, StockNews.com started coverage on iBio in a research note on Saturday, April 20th. They issued a sell rating for the […]